The Indian government is increasing its monitoring efforts in response to the rapid introduction of generic formulations of GLP-1 receptor agonists in the pharmaceutical market. This class of drugs, designed to treat type 2 diabetes and...
On April 1, the Government of India announced comprehensive guidelines concerning the usage, risks, and regulation of GLP-1 (glucagon-like peptide-1) drugs. These medications are primarily designed to assist individuals with diabetes, specifically targeting type 2 diabetes,...
